Literature DB >> 22429904

Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y.

Mallory E Bowers1, Dennis C Choi, Kerry J Ressler.   

Abstract

The neural circuitry of fear likely underlies anxiety and fear-related disorders such as specific and social phobia, panic disorder, and posttraumatic stress disorder. The primary pharmacological treatments currently utilized for these disorders include benzodiazepines, which act on the GABAergic receptor system, and antidepressants, which modulate the monamine systems. However, recent work on the regulation of fear neural circuitry suggests that specific neuropeptide modulation of this system is of critical importance. Recent reviews have examined the roles of the hypothalamic-pituitary-adrenal axis neuropeptides as well as the roles of neurotrophic factors in regulating fear. The present review, instead, will focus on three neuropeptide systems which have received less attention in recent years but which are clearly involved in regulating fear and its extinction. The endogenous opioid system, particularly activating the μ opioid receptors, has been demonstrated to regulate fear expression and extinction, possibly through functioning as an error signal within the ventrolateral periaqueductal gray to mark unreinforced conditioned stimuli. The cholecystokinin (CCK) system initially led to much excitement through its potential role in panic disorder. More recent work in the CCK neuropeptide pathway suggests that it may act in concordance with the endogenous cannabinoid system in the modulation of fear inhibition and extinction. Finally, older as well as very recent data suggests that neuropeptide Y (NPY) may play a very interesting role in counteracting stress effects, enhancing extinction, and enhancing resilience in fear and stress preclinical models. Future work in understanding the mechanisms of neuropeptide functioning, particularly within well-known behavioral circuits, are likely to provide fascinating new clues into the understanding of fear behavior as well as suggesting novel therapeutics for treating disorders of anxiety and fear dysregulation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429904      PMCID: PMC3532931          DOI: 10.1016/j.physbeh.2012.03.004

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  129 in total

1.  Regional distribution of Y-receptor subtype mRNAs in rat brain.

Authors:  R M Parker; H Herzog
Journal:  Eur J Neurosci       Date:  1999-04       Impact factor: 3.386

2.  Anxiolytic activity of NPY receptor agonists in the conflict test.

Authors:  K T Britton; S Southerland; E Van Uden; D Kirby; J Rivier; G Koob
Journal:  Psychopharmacology (Berl)       Date:  1997-07       Impact factor: 4.530

3.  Differential projections of the infralimbic and prelimbic cortex in the rat.

Authors:  Robert P Vertes
Journal:  Synapse       Date:  2004-01       Impact factor: 2.562

4.  Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.

Authors:  K Tatemoto; M Carlquist; V Mutt
Journal:  Nature       Date:  1982-04-15       Impact factor: 49.962

5.  Modulation of memory processing by neuropeptide Y varies with brain injection site.

Authors:  J F Flood; M L Baker; E N Hernandez; J E Morley
Journal:  Brain Res       Date:  1989-11-27       Impact factor: 3.252

6.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

7.  Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice.

Authors:  Rose-Marie Karlsson; Andrew Holmes; Markus Heilig; Jacqueline N Crawley
Journal:  Pharmacol Biochem Behav       Date:  2005-01-25       Impact factor: 3.533

8.  Immunolocalization of CCK1R in rat brain using a new anti-peptide antibody.

Authors:  Linda D Mercer; Philip M Beart
Journal:  Neurosci Lett       Date:  2004-04-08       Impact factor: 3.046

9.  Naloxone and shock-elicited freezing in the rat.

Authors:  M S Fanselow; R C Bolles
Journal:  J Comp Physiol Psychol       Date:  1979-08

10.  Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test.

Authors:  M Heilig; S McLeod; G K Koob; K T Britton
Journal:  Regul Pept       Date:  1992-09-03
View more
  52 in total

1.  ΔFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.

Authors:  David M Dietz; Pamela J Kennedy; Haosheng Sun; Ian Maze; Amy M Gancarz; Vincent Vialou; Ja Wook Koo; Ezekiell Mouzon; Subroto Ghose; Carol A Tamminga; Eric J Nestler
Journal:  Neuropsychopharmacology       Date:  2013-09-26       Impact factor: 7.853

2.  Plasma neuropeptide Y levels in Chinese patients with primary insomnia.

Authors:  Qiaoting Huang; Jiwu Liao; Yaping Liu; Huajun Liang; Ping Ma; Jiyang Pan
Journal:  Sleep Breath       Date:  2014-09-27       Impact factor: 2.816

3.  Data Independent Acquisition Mass Spectrometry Method for Improved Neuropeptidomic Coverage in Crustacean Neural Tissue Extracts.

Authors:  Kellen DeLaney; Lingjun Li
Journal:  Anal Chem       Date:  2019-04-04       Impact factor: 6.986

Review 4.  Challenges and recent advances in mass spectrometric imaging of neurotransmitters.

Authors:  Erin Gemperline; Bingming Chen; Lingjun Li
Journal:  Bioanalysis       Date:  2014-02       Impact factor: 2.681

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 6.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

Review 7.  The nature of individual differences in inhibited temperament and risk for psychiatric disease: A review and meta-analysis.

Authors:  J A Clauss; S N Avery; J U Blackford
Journal:  Prog Neurobiol       Date:  2015-03-14       Impact factor: 11.685

Review 8.  [Stress-induced hyperalgesia (SIH) as a consequence of emotional deprivation and psychosocial traumatization in childhood : Implications for the treatment of chronic pain].

Authors:  U T Egle; N Egloff; R von Känel
Journal:  Schmerz       Date:  2016-12       Impact factor: 1.107

Review 9.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

10.  Neuropeptidergic signaling partitions arousal behaviors in zebrafish.

Authors:  Ian G Woods; David Schoppik; Veronica J Shi; Steven Zimmerman; Haley A Coleman; Joel Greenwood; Edward R Soucy; Alexander F Schier
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.